% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ellingson:141668,
      author       = {B. M. Ellingson and L. E. Abrey and J. Garcia and O. Chinot
                      and W. Wick$^*$ and F. Saran and R. Nishikawa and R.
                      Henriksson and W. P. Mason and R. J. Harris and K. Leu and
                      D. C. Woodworth and A. Mehta and C. Raymond and A. Chakhoyan
                      and W. B. Pope and T. F. Cloughesy},
      title        = {{P}ost-chemoradiation volumetric response predicts survival
                      in newly diagnosed glioblastoma treated with radiation,
                      temozolomide, and bevacizumab or placebo.},
      journal      = {Neuro-Oncology},
      volume       = {20},
      number       = {11},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2018-01939},
      pages        = {1525 - 1535},
      year         = {2018},
      abstract     = {In the current study we used contrast-enhanced T1
                      subtraction maps to test whether early changes in enhancing
                      tumor volume are prognostic for overall survival (OS) in
                      newly diagnosed glioblastoma (GBM) patients treated with
                      chemoradiation with or without bevacizumab (BV).Seven
                      hundred ninety-eight patients (404 BV and 394 placebo) with
                      newly diagnosed GBM in the AVAglio trial (NCT00943826) had
                      baseline MRI scans available, while 337 BV-treated and 269
                      placebo-treated patients had >4 MRI scans for response
                      evaluation. The volume of contrast-enhancing tumor was
                      quantified and used for subsequent analyses.A decrease in
                      tumor volume during chemoradiation was associated with a
                      longer OS in the placebo group (hazard ratio [HR] = 1.578, P
                      < 0.0001) but not BV-treated group (HR = 1.135, P = 0.4889).
                      Results showed a higher OS in patients on the placebo arm
                      with a sustained decrease in tumor volume using a
                      post-chemoradiation baseline (HR = 1.692, P = 0.0005), and a
                      trend toward longer OS was seen in BV-treated patients (HR =
                      1.264, P = 0.0724). Multivariable Cox regression confirmed
                      that sustained response or stable disease was prognostic for
                      OS (HR = 0.7509, P = 0.0127) when accounting for age (P =
                      0.0002), KPS (P = 0.1516), postsurgical tumor volume (P <
                      0.0001), O6-methylguanine-DNA methyltransferase status (P <
                      0.0001), and treatment type (P = 0.7637) using the
                      post-chemoradiation baseline.The post-chemoradiation
                      timepoint is a better baseline for evaluating efficacy in
                      newly diagnosed GBM. Early progression during the
                      maintenance phase is consequential in predicting OS,
                      supporting the use of progression-free survival rates as a
                      meaningful surrogate for GBM.},
      cin          = {G370},
      ddc          = {610},
      cid          = {I:(DE-He78)G370-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29897562},
      pmc          = {pmc:PMC6178278},
      doi          = {10.1093/neuonc/noy064},
      url          = {https://inrepo02.dkfz.de/record/141668},
}